Page last updated: 2024-10-24

buspirone and Stroke

buspirone has been researched along with Stroke in 8 studies

Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
" Buspirone was administered to 16 depressed poststroke (DPS), 10 non-depressed post-stroke (NDPS) patients, and 10 male healthy controls (HCs), to evaluate serotonin (5-HT) function."7.70The prolactin response to buspirone in poststroke depression: a preliminary report. ( Erol, A; Sevinçok, L, 2000)
"Treatment with buspirone (3 mg/kg p."5.91Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats. ( Joshi, M; Patel, BM; Shah, D; Shah, J, 2023)
" The second trial randomised 94 stroke patients, also with co-morbid anxiety and depression, to receive buspirone hydrochloride or standard care."4.87Interventions for treating anxiety after stroke. ( Campbell Burton, CA; Gillespie, D; Holmes, J; Knapp, P; Lightbody, CE; Murray, J; Watkins, CL, 2011)
" Buspirone was administered to 16 depressed poststroke (DPS), 10 non-depressed post-stroke (NDPS) patients, and 10 male healthy controls (HCs), to evaluate serotonin (5-HT) function."3.70The prolactin response to buspirone in poststroke depression: a preliminary report. ( Erol, A; Sevinçok, L, 2000)
"Treatment with buspirone (3 mg/kg p."1.91Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats. ( Joshi, M; Patel, BM; Shah, D; Shah, J, 2023)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Shah, D1
Joshi, M1
Shah, J1
Patel, BM1
Conti, S1
Spalletti, C1
Pasquini, M1
Giordano, N1
Barsotti, N1
Mainardi, M1
Lai, S1
Giorgi, A1
Pasqualetti, M1
Micera, S1
Caleo, M1
Knapp, P2
Campbell Burton, CA2
Holmes, J2
Murray, J2
Gillespie, D2
Lightbody, CE2
Watkins, CL2
Chun, HY1
Lewis, SR1
van der Worp, HB1
Macleod, MR1
Bath, PM1
Demotes, J1
Durand-Zaleski, I1
Gebhardt, B1
Gluud, C1
Kollmar, R2
Krieger, DW1
Lees, KR1
Molina, C1
Montaner, J1
Roine, RO1
Petersson, J1
Staykov, D1
Szabo, I1
Wardlaw, JM1
Schwab, S2
Schellinger, PD1
Steigleder, T1
Köhrmann, M1
Lyden, P1
Ernstrom, K1
Cruz-Flores, S1
Gomes, J1
Grotta, J1
Mullin, A1
Rapp, K1
Raman, R1
Wijman, C1
Hemmen, T1
Sevinçok, L1
Erol, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke[NCT01833312]Phase 398 participants (Actual)Interventional2013-07-31Terminated (stopped due to Slow recruitment, cessation of funding)
Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke[NCT01123161]Phase 2/Phase 3120 participants (Actual)Interventional2010-06-30Terminated (stopped due to The ICTuS 2 portion of the trial has been halted and data will be analyzed.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

90 Day Mortality

Mortality prior to the 90-day evaluation. (NCT01123161)
Timeframe: 90 days

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia5
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment10

Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset

Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall. (NCT01123161)
Timeframe: 48 hours

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia13
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment9

Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset

Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage. (NCT01123161)
Timeframe: 48 hours

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia2
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment1

Incidence of Pneumonia

Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness (NCT01123161)
Timeframe: 7 days or discharge whichever comes first

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia6
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment12

NIHSS Scores at 90 Days

The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit. (NCT01123161)
Timeframe: 90 days

Interventionunits on a scale (Mean)
Group1: IV t-PA and Normothermia6.1
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment4.8

The Barthel Index Measure of Activities of Daily Living;

The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment. (NCT01123161)
Timeframe: 90 days

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia25
Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment24

The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment.

Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability (NCT01123161)
Timeframe: 90 days

Interventionparticipants (Number)
Group1: IV t-PA and Normothermia21
Group 2 : IV t-PA and Hypothermia21

Reviews

2 reviews available for buspirone and Stroke

ArticleYear
Interventions for treating anxiety after stroke.
    The Cochrane database of systematic reviews, 2017, 05-23, Volume: 5

    Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Depression; Humans; Middle Aged; Par

2017
Interventions for treating anxiety after stroke.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Humans; Paroxetine; Psychotherapy; R

2011

Trials

2 trials available for buspirone and Stroke

ArticleYear
EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:5

    Topics: Analgesics, Opioid; Anti-Anxiety Agents; Brain Ischemia; Buspirone; Clinical Protocols; Europe; Huma

2014
Determinants of effective cooling during endovascular hypothermia.
    Neurocritical care, 2012, Volume: 16, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Area Under Curve; Bu

2012

Other Studies

4 other studies available for buspirone and Stroke

ArticleYear
Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats.
    Molecular and cellular biochemistry, 2023, Volume: 478, Issue:9

    Topics: Animals; Buspirone; Cachexia; Cytokines; Endothelin-1; Glucose; Interleukin-6; Lipids; Muscle, Skele

2023
Combining robotics with enhanced serotonin-driven cortical plasticity improves post-stroke motor recovery.
    Progress in neurobiology, 2021, Volume: 203

    Topics: Animals; Buspirone; Mice; Neuronal Plasticity; Recovery of Function; Serotonin; Stroke; Stroke Rehab

2021
Ice-cold saline for the induction of mild hypothermia in patients with acute ischemic stroke: a pilot study.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Acute Disease; Aged; Analgesics, Opioid; Blood Cell Count; Blood Chemical Analysis; Brain Ischemia;

2009
The prolactin response to buspirone in poststroke depression: a preliminary report.
    Journal of affective disorders, 2000, Volume: 59, Issue:2

    Topics: Adult; Aged; Buspirone; Case-Control Studies; Depression; Dominance, Cerebral; Female; Humans; Male;

2000